Frontlight ResearchEarly access
WithdrawnPhase 1/2
Evaluation the Safety and Efficacy of Cilostazol in Treatment of Patients With Fatty Liver Disease
Key facts
- Who runs it
- Sadat City University
- Where
- Egypt1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Withdrawn
- Phase
- Phase 1/2
- Started
- 16 Feb 2021
- Ended
- 31 Dec 2024
- Type of study
- Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
- Treatments tested
- Cilostazol 50 MG
- Placebo
- Record updated
- 14 July 2025
- Why it stopped
- Institutional and funding constrains
Who can take part
- Age
- 18 years to 60 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 17 criteriaShow less
Who can take part
- Adults between 18 and 60 years of age, both men and women,
- Clinical diagnosis of NAFLD, confirmed by imaging exams,
- Patients who present levels above the reference values of ALT, AST and ferritin
Who cannot take part
- Patients with established prior diagnosis of chronic noncommunicable disease (congestive heart failure, decompensated or severe lung disease, neoplasms, renal disease, advanced liver disease - Child Pugh C classification)
- Users of illicit drugs
- Patients with ingestion of medications such as steroids, estrogens, amiodarone, warfarin, anti-convulsants, antipsychotics, tamoxifen or other chemotherapeutic agents in the last 6 months
- Wilson's disease
- Viral or autoimmune hepatitis
- HIV virus carriers
- Patients with clinically manifest infections or inflammation, surgery, trauma or hospitalization in the last 30 days
- Chronic non-hepatic degenerative diseases (sclerosis, Parkinson's disease or -Alzheimer's disease)
- Women in the menacing period, with the exception of those who have performed definitive sterilization, such as hysterectomy or tubal ligation
- Patients with schistosomiasis
- Hemochromatosis
- Woman who is breastfeeding
- Patients with an intake of more than 20 g / day of alcohol and / or past alcoholism with abstention less than 6 months
- Patients who do not participate in all stages of the research
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
The aim of the current study is to evaluate the safety and efficay of cilostazol in treatment of patients with fatty liver disease. Several previous reports have shown that cilostazol ameliorates lipid imbalances in NAFLD. Cilostazol appeared to exert beneficial effects against NAFLD
The 2 groups in the trial
- CilostazolTreatment being tested
Treatment: Cilostazol 50 MG
- PlaceboPlacebo, for comparison
Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Evaluation the Safety and Efficacy of Cilostazol in Treatment of Patients With Fatty Liver Disease: A Randomized, Controlled Trial.
- Record updated
- 14 July 2025